Followers | 30 |
Posts | 3306 |
Boards Moderated | 0 |
Alias Born | 08/21/2015 |
Thursday, May 05, 2016 8:22:33 AM
"Following is a response to your questions that includes some of the differentiation and advantages of PRO 140 over Ibalizumab.
Ibalizumab is administered via IV not subcutaneous and is for terminal patients (very small market). CytoDyn believes that the subcutaneous formulation is in Phase 1.
Ibalizumab is administered at the hospital once every two weeks and following infusion the patient's energy level can be very low because this product binds to CD4 receptor of all cells that have CD4.
Please see below chart of PRO 140 versus Ibalizumab and note the following: It takes 10mg/kg of Ibalizumab to reduce the viral load (VL) to about 1.4log after 14 days. With PRO 140 it took 10 days to reduce the VL to 1.7 log (the max which is not included on the curve was 2.5log). To put this into perspective, 1.4log represents about a 25 folds drop in VL and 2.5log is about 318 folds drop in VL.
Further, it took only 14 more days for VL following treatment with Ibalizumab arm to return to the original level but with PRO 140 it took another 50 days.
With 3 mg/kg the Ibalizumab VL drop is (at its Nadir level) .5log with PRO 140 5mg/kg the nadir is 1log (more than three times potent- [.5log = 3 fold, 1log = 10 fold drop]."
Recent CYDY News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:01:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:01:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 10:15:19 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM